Licensed under CC BY 4.0. Attribution is required when you publish or redistribute this Template or an adapted version to the public. Attribution is not required merely because you use or adapt the Template for your own business or legal purposes, including preparing, negotiating, signing, or exchanging an agreement with a counterparty. License details.
Arkansas, US · Research
Clinical Trial Agreement
Contract Template For Arkansas, US
An Arkansas site and sponsor agreement for an adult FDA-regulated investigational-device study, with IDE and IRB activation, informed consent, device accountability, safety reporting, confidential records, budget, injury coverage and publication rights.
CLINICAL TRIAL AGREEMENT
CLINICAL TRIAL AGREEMENT
Arkansas, US
Made on: [date]
Device Sponsor: [full legal name and entity type], of [address] (Sponsor).
Study Site: [full legal name and entity type], an Arkansas hospital or clinic at [address] (Site).
Site Investigator: [name, professional license and address] (Investigator).
1. Authorized investigation
Sponsor engages Site to conduct the prospective adult clinical investigation in Exhibit A (Investigation) using the investigational medical device identified there (Device). The Protocol, investigational device exemption or lawful abbreviated IDE basis, IRB approval, informed-consent form and Sponsor instructions govern technical conduct, but do not change this Agreement's payment, ownership, publication or liability terms. No subject may enroll until Sponsor gives written activation after confirming FDA and IRB authorization, Investigator's signed agreement and financial disclosures, staff training, Site capability and Device availability.
The Investigation does not cover a humanitarian-use device, emergency use without consent, children, prisoners, pregnant participants specifically targeted as a vulnerable population, or use outside the approved Protocol. Sponsor shall perform its duties under 21 CFR Part 812, including regulatory submissions, investigator selection, monitoring, safety evaluation and required reports. Site and Investigator shall perform applicable investigator duties, maintain professional and facility authority, and not represent that the Device is safe or effective.
2. Enrollment and care
Site shall recruit fairly, verify eligibility and obtain the subject's dated signature on the current IRB-approved consent before any Investigation procedure. It shall give the subject a copy and preserve every version used. Consent may not waive legal rights or release any person from negligence. Investigator controls medical decisions, may withdraw a subject for welfare, and may depart from the Protocol without prior approval only when necessary to protect life or physical well-being, followed by required Sponsor and IRB reports.
Site shall perform Protocol procedures, document contemporaneously, protect blinding, report deviations and keep Sponsor informed of enrollment. Standard clinical care remains Site's responsibility. Site shall not bill a subject or payer for the Device or any procedure paid by Sponsor, and may bill routine care only when lawful, medically necessary and accurately disclosed.
3. Device custody and events
Sponsor shall deliver labeled Devices and necessary manuals, training and updates without charge. Site shall restrict Device access to authorized personnel; record serial or lot number, receipt, subject use, return, repair and disposition; store and maintain Devices as directed; and not modify, reverse engineer, transfer or use a Device outside the Investigation. Sponsor retains ownership of Devices not implanted in subjects. At close-out Site shall return or dispose of Devices only under Sponsor's lawful written direction.
Site shall report unanticipated adverse device effects, deaths, serious injuries, complaints, malfunctions and device deficiencies within the Protocol and legally required periods, with prompt follow-up. Sponsor shall promptly assess reports, inform Site and the IRB of material new risks, and direct lawful corrective action. Each party shall make reports assigned to it under 21 CFR Part 812. Sponsor shall determine and perform any ClinicalTrials.gov registration and results duty as responsible party unless Exhibit A expressly and lawfully assigns it to Investigator with written acceptance.
4. Case data, source records and confidentiality of patient information
Site remains custodian of its original patient medical records and original source documents. Sponsor owns the electronic case-report forms, compiled study database and analyses it produces. Site shall enter complete and verifiable data, answer supported queries and retain Investigation records for the period required by 21 CFR 812.140 and 812.145 and any longer applicable duty; Sponsor shall notify Site when regulatory retention ends. Neither party may destroy a record subject to a legal hold.
Only personnel authorized by Site may access medical records. Sponsor monitors and auditors may inspect identifiable source information at Site solely to verify the Investigation and only under a valid HIPAA authorization, IRB waiver or other lawful basis. The parties shall use coded identifiers in transfers, apply reasonable administrative, physical and technical safeguards, limit access to the authorized purpose and notify each other of any impermissible access, use or disclosure within two calendar days. Sponsor may not use identifiable information for advertising, employment, eligibility, insurance or unrelated research. Each party shall satisfy its own HIPAA and Arkansas legal duties; no business-associate status is created solely by monitoring research.
5. Review and official access
Sponsor may monitor and audit relevant personnel, facilities, Device accountability and records during normal hours on reasonable notice, and may conduct prompt for-cause review when safety or data integrity reasonably requires. Site shall permit FDA and other lawful authorities to inspect records and facilities as required, and notify Sponsor promptly unless prohibited. Sponsor shall share material findings affecting Site; Site shall document timely corrective action. Monitoring does not transfer Site's responsibility or make Sponsor responsible for Site's independent clinical care.
6. Payment and research-related injury
Sponsor shall pay the fair-market-value fees in Exhibit B for work actually completed, plus approved noncancelable close-out costs. Site shall invoice with the listed supporting detail. Payment is not based on the outcome, referrals, prescriptions, purchases or the volume or value of business outside the Investigation. Site shall disclose and obtain IRB approval for subject payments and shall not pay Study Staff improper enrollment bonuses.
Sponsor shall reimburse reasonable and necessary medical expenses for an injury caused by the Device or a Protocol-required procedure that the subject would not have received outside the Investigation, excluding amounts caused by Site's or Investigator's negligence, intentional misconduct or material Protocol violation, or the subject's underlying condition. The consent shall state the available arrangement without requiring waiver of rights. Site shall give prompt notice and reasonable clinical documentation. Sponsor and Site shall maintain the insurance shown in Exhibit A.
7. Results, inventions and protected business information
Site may submit a good-faith manuscript after the earlier of Sponsor's first multi-site publication or eighteen months after Site close-out. Site shall provide a draft thirty days before submission. Sponsor may identify its confidential information and request a delay of up to sixty additional days to protect a patent, but shall not require suppression or misleading alteration of results. Site may disclose safety information whenever law, the IRB or patient welfare requires.
A party owns inventions made solely by its personnel outside the Investigation or without the other's confidential material. Sponsor owns an invention conceived solely from the Device's design or Sponsor's confidential technical information in performing the Protocol; Site owns a general clinical method or Site technology. Joint inventions follow United States inventorship law. Site shall disclose a potentially Sponsor-owned invention and execute confirming documents at Sponsor's expense. Sponsor grants Site a noncommercial license to use its Site-level results for patient care, education and research after permitted publication.
Each party shall protect the other's nonpublic information marked or reasonably understood as confidential and use it only for this Agreement. Information lawfully public, already possessed without duty, independently developed or lawfully obtained elsewhere is excluded. Required disclosure is allowed after prompt notice where lawful.
8. Claims, duration and early close
Sponsor shall defend and indemnify Site and its personnel from third-party claims to the extent caused by a Device defect, Sponsor's instructions or Sponsor breach, except to the extent caused by the protected person's negligence, willful misconduct or Protocol violation. Site shall defend and indemnify Sponsor from third-party claims to the extent caused by Site's negligence, willful misconduct or material Protocol violation. Protection requires prompt notice and cooperation; no settlement may admit the protected party's fault or impose an obligation without its consent.
This Agreement continues through regulatory close-out. Either party may terminate on thirty days' notice, or immediately for an unreasonable subject risk, loss of FDA or IRB authorization, material uncured breach, debarment affecting performance or insolvency. Site may suspend enrollment immediately on Investigator's safety judgment. Site shall stop enrollment, arrange safe subject transition and follow-up, reconcile Devices, complete earned records and preserve them. Sponsor shall pay earned amounts and approved close-out costs. Records, privacy, payment, subject injury, publication, inventions, confidentiality and indemnity survive as their purposes require.
9. Final terms
Sponsor and Site are independent contractors. Investigator acknowledges duties but is not personally liable for Site's payment obligations. Assignment requires written consent, except Sponsor may assign the entire Investigation and regulatory authorization to a qualified successor that assumes every duty. Notices take effect on actual receipt at Exhibit A contacts. Arkansas law governs alongside controlling federal law. Government and IRB authority and nonwaivable subject rights are not limited. This Agreement, Exhibits and final Protocol are the complete agreement; changes require signatures except an immediately required safety measure. Counterparts and electronic signatures are effective.
EXHIBIT A — INVESTIGATION
Protocol title/number/version/date: [details]. Device/IDE or abbreviated IDE basis: [details].
Site, Investigator and target enrollment: [details]. IRB: [name]. Investigation dates: [details].
ClinicalTrials.gov responsible party: [details].
Sponsor regulatory/safety/notice contacts: [details]. Site regulatory/privacy/notice contacts: [details].
Insurance: Sponsor [details]; Site [details].
EXHIBIT B — BUDGET
Activation/start-up: [amount]. Per completed subject milestone: [table]. Device handling: [amount]. Close-out: [amount]. Invoice timing: [details].
SPONSOR: ____________________ Name/title: [name and title] Date: [date]
SITE: ____________________ Name/title: [name and title] Date: [date]
INVESTIGATOR ACKNOWLEDGMENT: ____________________ Date: [date]
More templates for Arkansas, US
Template
Agricultural Production Agreement
Arkansas, US Agriculture
Free · Markdown · WordView template
Template
Franchise Agreement
Arkansas, US Franchise
Free · Markdown · WordView template
Template
HIPAA Business Associate Agreement
Arkansas, US Healthcare
Free · Markdown · WordView template
Template
LLC Membership Interest Subscription Agreement
Arkansas, US Business Formation
Free · Markdown · WordView template
Template
Landscaping Services Agreement
Arkansas, US Services
Free · Markdown · WordView template
Template
Output Purchase Agreement
Arkansas, US Goods & Supply
Free · Markdown · WordView template
Template
Patent License Agreement
Arkansas, US Intellectual property
Free · Markdown · WordView template
Template
Pet Grooming Services Agreement
Arkansas, US Services
Free · Markdown · WordView template
Template
Pledge Agreement
Arkansas, US Finance & security
Free · Markdown · WordView template
Template
Stock Exchange Agreement
Arkansas, US Corporate & shares
Free · Markdown · WordView template
Template
Subcontractor Agreement
Arkansas, US Construction
Free · Markdown · WordView template
Template
Talent Representation Agreement
Arkansas, US Media and Entertainment
Free · Markdown · WordView template
Template
Technology Transfer Agreement
Arkansas, US Technology
Free · Markdown · WordView template
Template
Wholesale Purchase Agreement
Arkansas, US Sale of Goods
Free · Markdown · WordView template